MDGL
Madrigal Pharmaceuticals margins
- Stocks
- Healthcare
- NASDAQ: MDGL
- Margins
Madrigal Pharmaceuticals records its operating margin is negative at -25.1%, its EBITDA margin is negative at -22.4%, and its net margin is negative at -25.3%, with a gross margin of 91.5%, an operating margin of -25.1%, an EBITDA margin of -22.4%, and a net margin of -25.3%. Margin expansion was strongest in operating margin, which rose by 35 percentage points. Gross margin had the strongest contraction, falling by 4.8 percentage points.
MDGL margin history
Over the last 3 years, Madrigal Pharmaceuticals recorded average margins of 95.06% gross, -548.03% operating, -507.32% EBITDA, and -524.52% net. Madrigal Pharmaceuticals's current performance shows that operating, EBITDA, and net margins are above their three-year averages and gross margin is below its three-year average.
MDGL margin expansion
Operating margin expanded by 35 percentage points, EBITDA margin by 29.4 percentage points, and net margin by 29.4 percentage points, but gross margin contracted by 4.8 percentage points.
MDGL Gross margin
Over the last 3 years, the average gross margin for Madrigal Pharmaceuticals was 95.06%. The latest gross margin for Madrigal Pharmaceuticals is 91.5%, 3.6 percentage points below its three-year average. Madrigal Pharmaceuticals's gross margin ranged from a low of 91.5% in Jun 2026 to a high of 96.6% in Mar 2025.
MDGL Operating margin
The average operating margin for Madrigal Pharmaceuticals was -548.03% during the last 3 years. The latest operating margin for Madrigal Pharmaceuticals is -25.1%, 522.9 percentage points above its three-year average. The operating margin for Madrigal Pharmaceuticals moved between -3,622.7% in Jun 2024 and -25.1% in Jun 2026.
MDGL EBITDA margin
The average EBITDA margin for Madrigal Pharmaceuticals was -507.32% in the last 3 years. Madrigal Pharmaceuticals's current EBITDA margin is -22.4% and is 484.9 percentage points above its three-year average. The EBITDA margin for Madrigal Pharmaceuticals moved between -3,380% in Jun 2024 and -22.4% in Jun 2026.
MDGL Net margin
Over the last 3 years, the average net margin for Madrigal Pharmaceuticals was -524.52%. Right now, Madrigal Pharmaceuticals's current net margin is -25.3%, which is 499.2 percentage points above its three-year average. Madrigal Pharmaceuticals's net margin ranged from a low of -3,487.1% in Jun 2024 to a high of -25.3% in Jun 2026.
MDGL margin group comparison
Madrigal Pharmaceuticals's gross margin of 91.5% is higher than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 68.3%, Madrigal Pharmaceuticals's gross margin is 34% higher.
Frequently asked questions
What is Madrigal Pharmaceuticals's gross margin?
The current gross margin for MDGL is 91.5% as of Jun 30, 2026.
What is Madrigal Pharmaceuticals's operating margin?
As of Jun 30, 2026, MDGL has a negative operating margin of -25.1%.
What is Madrigal Pharmaceuticals's EBITDA margin?
For the period ending Jun 30, 2026, MDGL recorded an EBITDA margin of -22.4%.
What is Madrigal Pharmaceuticals's net margin?
As of Jun 30, 2026, MDGL has a net margin of -25.3%.
What are the average margins of MDGL?
Madrigal Pharmaceuticals's gross, operating, EBITDA, and net margins averaged 95.1% gross, -548.0% operating, -507.3% EBITDA, and -524.5% net over the last 3 years.
What are the highest historical margins of MDGL?
Madrigal Pharmaceuticals's highest recorded margins during the past 5 years were 96.6% gross in Mar 2025, -25.1% operating in Jun 2026, -22.4% EBITDA in Jun 2026, and -25.3% net in Jun 2026.
What are the lowest historical margins of MDGL?
Across the 5-year period, MDGL posted its lowest margins at 91.5% gross in Jun 2026, -3,622.7% operating in Jun 2024, -3,380% EBITDA in Jun 2024, and -3,487.1% net in Jun 2024.